Drug Trial Radar · NCT01096134
Mother - Daughter Initiative (MDI) in Cervical Cancer Prevention
Last checked: Nov 19, 2026Latest source record: Oct 12, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8,000
Actual
Start
Jan 2011
Primary completion
Nov 2012
Study completion Nov 2012
Sponsor
- Lead sponsor
- JhpiegoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Mar 30, 2010
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- Female only, from 9 years, up to 13 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The Mother-Daughter Initiative (MDI) will test the feasibility and acceptability of a strategy to deliver comprehensive cervical cancer prevention services in Thailand and the Philippines by integrating the HPV vaccine for girls ages 9-13 into already successful screening and treatment programs for mothers.
Conditions
- Cervical Cancer
Interventions
HPV Vaccine (Gardasil)Biological
HPV Vaccine Administration: According to the CDC, Gardasil should be delivered through a series of three intra-muscular injections over a six-month period. The second and third doses should be given two and six months after the first dose. The vaccine can be administered at the same visit as other age-appropriate vaccines, such as Tdap, Td, MCV4, influenza, and hepatitis B vaccines. Providers should consider a 15-minute waiting period for vaccine recipients following vaccination. FDA's Approval of Gardasil (June 8, 2006) lists the following information on product Formulation: Each 0.5 mL dose of the vaccine contains: 20 mcg of HPV 6 L1 protein 40 mcg of HPV 11 L1 protein 40 mcg of HPV 16 L1 protein 20 mcg of HPV 18 L1 protein 225 mcg aluminum (as amorphous aluminum hydroxyphosphate sulfate adjuvant) 9.56 mg of sodium chloride 0.78 mg of L-histidine 50 mcg of polysorbate 80 35 mcg of sodium borate water for injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determine the population coverage of HPV vaccination of girls aged 9-13 offered within the context of cervical cancer screening and treatment of mothersTime frame: 18 months
Locations
10 sites in 2 countries. Site status is shown where the registry gives one.
Minglanilla
Cebu, Philippines
Los Banos
Quezon, Philippines
Pagbilao Health Center
Quezon, Philippines
Ban Yuanlae District Health Center
Ban Phon Ko, Thailand
Ban Mai Daeng
Nakhon Si Thammarat, Nakornsri, Thailand
Ban Pai Ta Health Center
Nakhon Si Thammarat, Nakornsri, Thailand
Health promotion Clinic Number 11
Nakhon Si Thammarat, Nakisron, Thailand
Ban Pak Poon Health Center
Nakhon Si Thammarat, Nakornsri, Thailand
Maharat Nakhonsithammarat Primary Care Unit
Nakhon Si Thammarat, Nakornsri, Thailand
Pak-Panung District Health Center
Nakhon Si Thammarat, Nakornsri, Thailand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.